AlloMap® gene
expression testing is a non-invasive screening tool approved for use in heart
transplant recipients age 15 and older. Experience with AlloMap® in pediatric
heart transplant recipients is limited.
We sought to
describe the variations in AlloMap®
scores seen in pediatric heart transplant recipients. This is a retrospective study of all pediatric heart transplant
recipients with AlloMap® scoring at a single institution between 2013 and 2014.
All possible scores were recorded.
Other variables
recorded at the time of each AlloMap® score included immunosuppressive regimen,
patient demographics and endomyocardial biopsy (EMB) results.
